Incubation Time of Acute Human Immunodeficiency Virus (HIV) Infection and Duration of Acute HIV Infection Are Independent Prognostic Factors of Progression to AIDS by Vanhems, Philippe et al.
334
CONCISE COMMUNICATION
Incubation Time of Acute Human Immunodeficiency Virus (HIV) Infection
and Duration of Acute HIV Infection Are Independent Prognostic Factors
of Progression to AIDS
Philippe Vanhems,1 Bernard Hirschel,2
Andrew N. Phillips,3 David A. Cooper,4
Jeanette Vizzard,4 Joelle Brassard,5 and Luc Perrin2
1Laboratory of Epidemiology and Public Health, INSERM U271,
Universite´ Claude Bernard, and Epidemiology Unit, Edouard Herriot
Hospital, Lyon, France; 2Division of Infectious Diseases, University
Hospital, Geneva, Switzerland; 3Royal Free Centre for HIV Medicine
and Department of Primary Care and Population Sciences, Royal Free
and University College Medical School, London, United Kingdom;
4National Centre in HIV Epidemiology and Clinical Research,
Sydney, Australia; 5Institute of Social and Preventive Medicine,
University of Montreal, Montreal, Canada
The severity and the duration of acute human immunodeficiency virus (HIV) infection
(AHI) are associated with a faster rate of progression to AIDS, but the prognostic value of
the length of incubation time of AHI (IncAHI), defined as the time between HIV infection
and AHI, on progression to AIDS has not been assessed. We explored this issue prospectively
in 70 individuals with documented AHI and a known date of HIV infection. The median
IncAHI was 21.5 days (range, 5–70 days), and the median duration of AHI was 15.5 days
(range, 3–67 days). The adjusted relative hazard of progression to AIDS or to a CD4+ count
! /mL was 4.23 (95% confidence interval [CI], 1.40–12.73; ) for the patients3200 3 10 P = .01
with an IncAHI !21.5 days, compared with those with longer IncAHI, and was 3.53 (95%
CI, 1.09–11.36; ) for the patients with a duration of AHI 115.5 days, compared withP = .03
those with shorter duration. Both IncAHI and duration of AHI were independent predictors
of progression. This suggests that early pathogenic events before the onset of AHI influence
the rate of HIV disease progression.
Acute human immunodeficiency virus type 1 (HIV-1) infec-
tion (AHI) is a heterogeneous syndrome [1, 2]. Patients with
more severe symptoms during AHI and an AHI lasting 115
days tend to progress faster toward AIDS [3, 4]. Data on the
prognostic value of the incubation of AHI (IncAHI), defined
as the time between HIV infection and AHI, are lacking.
The objective of this investigation was to determine whether
the time from HIV infection until the onset of AHI is an in-
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dependent factor of progression to AIDS or toward a CD41
count ! /mL after adjustment for duration of AHI.3200 3 10
Methods
This prospective study included a total of 70 patients with AHI
for whom a date of HIV infection was known. These patients are
a subgroup of a larger cohort of Swiss and Australian individuals
described in detail elsewhere [1]. This cohort was initiated to study
the clinical features of AHI and the comparison of the rates of
disease progression by severity of AHI. The patients selected for
this investigation were those with symptomatic AHI and with a
date of HIV exposure reported in the data-collection form. The
onset of AHI was before the end of 1987 in 6 patients, between
1988 and 1991 in 19 patients, and between 1992 and December 31,
1995 in 45 patients. Patients were asked about the date of infection
at the time they presented with symptoms of AHI. The number of
sexual partners within the last year was 1 for 57 patients (81.4%),
2 for 5 patients (7.1%), and 12 for the remainder (11.4%). The
presumed route of HIV infection was self-reported; a total of 47
individuals (67%) reported infection by unprotected homosexual
intercourse, 6 (8.5%) by unprotected receptive oral sex, 11 by het-
erosexual intercourse (15.7%), 2 after syringe exchange (3%), 1 after
blood transfusion (1.4%), and 3 by another route not reported. The
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Figure 1. Probability of being free of clinical AIDS or not having
a CD41 cell count ! /mL for individuals with incubation of3200 3 10
acute human immunodeficiency virus (HIV) infection 121.5 days (solid
line) or !21.5 days (dashed line).
serostatus of patients’ partners was available for 11 individuals. In
2 cases (3%), the partner had AIDS, and in 9 cases (13%) he was
asymptomatic. The date of exposure was based on the patient’s
best estimate. IncAHI was defined as the time elapsed between the
date of HIV infection and the date of AHI onset. The clinical
features of AHI were recorded on standardized collection forms in
the 2 centers (in Geneva and Sydney) [1]. Clinical and laboratory
follow-up procedures were similar in both centers [1].
The laboratory criteria of AHI were (1) the presence of p24
antigenemia ( ) in patients with negative or indeterminate EIAn = 58
serology, (2) 2 bands on Western blots, one of which corresponded
to the env gene (gp 160, gp 120, gp 41; ) with a negative EIAn = 3
serology, and (3) a negative HIV-1 EIA test followed by a positive
HIV-1 EIA test within 6 months (median, 85 days; range, 4–188
days; ). HIV infection was confirmed in all patients by Westernn = 9
blots. CD41 cell counts were conducted in laboratories affiliated
with either university center. The laboratories in Geneva and Syd-
ney are national reference centers, and quality control testing is
done regularly. T cell subsets were measured by flow cytometry in
both locations.
Groups were compared by the x2 test or Fisher’s exact test for
categorical variables and by Student’s t test for continuous vari-
ables after logarthimic transformation, if necessary. Multiple linear
regression was used for calculate the association between IncAHI
and duration of AHI, after adjustment for confounders. The end-
point was AIDS according to the 1993 definition by the Centers
for Disease Control and Prevention or a first CD41 count
! /mL. Progression was calculated by the Kaplan-Meier3200 3 10
method, with the onset of AHI as time 0 and censoring at the last
visit or at June 30, 1995, to exclude the confounding effect of the
use of highly active antiretroviral therapy. Comparison of survival
distribution was based on the log-rank test. The Cox proportional
hazard model was used to estimate the adjusted relative hazard
(ARH) of disease progression. No patient was considered lost to
follow-up, defined as 1 year without knowledge of vital status. P
values !.05 were considered statistically significant. Analysis was
conducted with SPSS version 6.0 (SPSS, Chicago).
Results
The patients, 91% of whom were men, had a mean age of
30.6 years. Thirty-one patients were from Geneva and 39 from
Sydney. The mean IncAHI was 25.8 days, with a median of
21.5 days (range, 5–70 days), and did not differ by center
( ). The mean duration of AHI was 16.8 days, with aP = .15
median of 15.5 days (range, 3–67 days). The most common
symptoms at AHI were fever (91%), lethargy (84%), skin rash
(76%), headache (69%), myalgia (67%), arthralgia (41%), and
diarrhea (27%). No difference in symptom frequency or the
proportion of hospitalized patients (23%) was observed ac-
cording to IncAHI greater than or less than 21.5 days.
Adjusted regression analysis did not identify independent
variables associated with IncAHI ( for duration of AHI;P = .77
for age; for gender; for route of infec-P = .33 P = .50 P = .36
tion; for the center [Geneva vs. Sydney]).P = .17
The duration of follow up was 24.3 months for patients with
IncAHI below the median (21.5 days; group 1) and 24.2 months
for patients with IncAHI above the median (group 2; ).P = .9
Antiretroviral treatment was prescribed in a similar proportion
in the 2 groups ( ) at AHI (48%) and during follow upP = 1.00
(60% for group 1 and 51% for group 2; ). The meanP = .47
interval between AHI and the start of antiretroviral therapy
was 6.2 months for group 1 and 5.5 months for group 2
( ). The regimens prescribed at AHI for patients in groupP = .84
1 was single nucleoside reverse transcriptase inhibitor for 15
patients (43%), a combination of 2 nucleoside reverse tran-
scriptase inhibitors for 1 patient (6%), and a combination of
nucleoside reverse transcriptase inhibitor and acyclovir for 1
patient (6%); the regimens prescribed at AHI in group 2 were
a single nucleoside reverse transcriptase inhibitor for 15 patients
(43%), a combination of nucleoside reverse transcriptase in-
hibitor and acyclovir for 1 patient (6%), and a combination of
nucleoside reverse transcriptase inhibitor and nonnucleoside re-
trotranscriptase inhibitor for 1 patient (6%). The proportion of
patients treated within 3 months after AHI was similar between
the two centers (58% for Geneva and 41% for Sydney; P =
), and the total duration of antiretroviral was also similar.16
between the two centers (mean of 4.6 months for Geneva and
mean of 4.1 months for Sydney; ). The proportion ofP = .5
patients who received primary Pneumocystis carinii prophylaxis
was similar in both groups ( ). A total of 13 patients inP = .32
group 1 and 8 patients in group 2 reached the end point during
the follow-up. Six AIDS events occurred in group 1 (2 chronic
herpes simplex ulcerations 11 month, 2 cryptosporidiosis, 1
AIDS dementia complex, and 1 cytomegalovirus infection), and
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Table 1. Adjusted relative hazard of progression to AIDS or to a
CD41 cell count ! /mL.3200 3 10
Variable
Adjusted relative
hazard (95% CI) P
IncAHI !21.5 days 4.23 (1.40–12.73) .01
Duration of AHI >15.5 days 3.53 (1.09–11.36) .03
Antiretroviral treatment at AHI 0.28 (0.08–.94) .04
Primary Pneumocystsi carinii pneumonia
prophylaxis 0.50 (0.13–1.84) .30
Route of HIV infection
Homosexual intercourse vs. others 0.25 (0.02–2.16) .20
Center (Geneva vs. Sydney) 0.40 (0.11–1.30) .12
NOTE. All the variables of the table were in the model equation. Age was
not associated with progression ( ) and not included in the model. ModelP = .69
characteristics: 22 log likelihood, 83.556; x2, 24.513; 6 df; . CI, confi-P = .0004
dence interval; IncAHI, incubation of acute human immunodeficiency virus (HIV)
infection.
2 AIDS events occurred in group 2 (1 Mycobacterium avium
complex infection and 1 chronic herpes simplex ulceration 11
month). By use of the Kaplan-Meier analysis, the median of
progression to AIDS or to a CD41 cell count ! /mL3200 3 10
was 3.82 years (95% confidence interval [CI], 3.13–4.50) in
group 1 and 5.05 years (95% CI, 1.80–8.28) in group 2 (P =
; figure 1). One patient received protease inhibitors 243 days.03
after AHI for a period of 92 days; this individual was in group
1 and did not have AIDS during follow-up. Survival analysis
without this patient remained unchanged. By use of the Kaplan-
Meier method, the median of progression to AIDS or to a CD41
cell count ! /mL was 3.55 years (95% CI, 2.93–4.17)3200 3 10
for individuals with a duration of AHI greater than the median
(15.5 days) and 5.04 years (95% CI, 4.30–5.78) for those with
a duration of AHI less than the median ( ).P = .005
We calculated the ARH of progression using the proportional
hazard model after adjustment for the length of AHI and for
potential confounders (table 1). The multivariate model iden-
tified both IncAHI and duration of AHI as independent prog-
nostic factors of disease progression. Similar analysis with
IncAHI and AHI as continuous variables identified only a long
IncAHI (AHR, 0.95; 95% CI, 0.91–0.99; ) as protectiveP = .03
effect on disease progression. Among patients free of antire-
troviral treatment at AHI, the mean of CD41 within 1 month
after onset was 467/mL (SD, 271) for group 1 patients (n =
) and 604/mL (SD, 228) for group 2 patients ( ;14 n = 21 P =
) and the mean of CD41 at 2 months after onset was 637/.12
mL (SD, 263) for group 1 patients ( ) and 695/mL (SD,n = 19
325) for group 2 patients (a; ). The use of antiretroviralP = .52
therapy at AHI had a protective effect in this observational
cohort.
Discussion
The objective of this study was to identify the independent
prognostic value of the IncAHI and duration of AHI. Previ-
ously, early prognostic studies were done mostly at the onset
of AHI and/or at the time of HIV seroconversion, but few
investigations of IncAHI have been conducted. The question
of the validity of the reported date of HIV infection is central
and was ascertained on 3 grounds. First, the information was
collected prospectively, which reduced memory bias. Second,
the duration between infection and the onset of AHI was similar
to that in studies elsewhere [2, 5–8], in which IncAHI ranged
from 1 to 8 weeks. For example, IncAHI lasted 11–28 days for
Gaines et al. [5], 5–29 days (mean, 15 days) for Schacker et al.
[2], 2–3 weeks for Quin [6], and 3–6 weeks for Clark et al. [7].
Third, our results are consistent with data obtained from health-
care workers who developed AHI after needle-stick injuries [9].
In that case, the IncAHI reported was 14–28 days for Marcus
et al. [10], 25 days for Oksenhendler et al. [11], and 16 days
for Pratt et al. [12]. Although we cannot have total confidence
in individual measures of the IncAHI, we think it unlikely that
lack of precision would bias our results. For a bias to occur,
patients destined to progress faster toward AIDS would have
to systematically recall a presumed date of infection that was
later than the real date of infection. The occurrence of such a
systematic error does not seem plausible to us.
IncAHI was associated with progression toward AIDS in our
cohort independently of duration of AHI. Because this result
was obtained among individuals who reached a small number
of outcomes, confirmatory studies are needed with larger co-
horts. Pedersen et al. showed that duration of acute HIV in-
fection was associated with a faster progression to AIDS [3].
The rapid rate of disease progression observed in our cohort
was related to the absence of asymptomatic HIV seroconver-
tors. Our study was conducted among patients who, except for
1, received what is now regarded as suboptimal therapy, because
no protease inhibitors were administered until the end of follow-
up. This provided the opportunity to study the natural history
of disease progression without the confounding factor of highly
active antiretroviral therapy.
The present investigation suggests that initial pathogenetic
mechanisms could influence the rate of disease progression,
even before the onset of AHI. The mechanisms influencing the
length of IncAHI are not well understood. Because no specific
anti-HIV immune response can be measured during that period,
differences in the replicative capacities of HIV, in the interaction
of HIV and mucosal surfaces or in the reaction of the innate
immune system to HIV, could presumably play a role [13]. A
short IncAHI could mean that the virus has faster access to
the target cells. Investigations on the transition period between
IncAHI and onset of AHI could yield essential information on
the respective contribution of the viral replication [14] and im-
munological response [15] that determine the prognosis. The
impact of virus replication and its relationship to host genetic
factors also need to be investigated.
This study suggests both IncAHI and duration of AHI were
associated with the prognosis. These results confirm the key
place of early events on late prognosis of HIV infection.
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